Telitacicept for children with frequently relapsing or steroid-dependent nephrotic syndrome
Tests telitacicept in children with nephrotic syndrome that keeps returning or needs steroids.
Key facts
- Who runs it
- The Children's Hospital of Zhejiang University School of Medicine
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Study of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 20 people, planned
- Started
- 28 Nov 2023
- Expected to end
- 24 Oct 2027
- Type of study
- Interventional
- Treatments tested
- Telitacicept
- Record updated
- 21 August 2024
Who can take part
The trial is looking for children and teens with nephrotic syndrome that responds to steroids but often comes back, or that depends on steroids. It tests telitacicept for 52 weeks.
- Age
- 2 to 18 years
- Sex
- All sexes
- Disease stage
- Nephrotic syndrome that responds to steroids but relapses often, or needs steroids to stay controlled. Kidney function must be normal (estimated glomerular filtration rate ≥90ml/ min/1.73m2). At enrolment, urine protein must be low: morning urine protein <1+ or urine protein-creatinine ratio <0.2g/g (<20 mg/ mmol) for 3 days in a row or more.
- Earlier treatment
- No rituximab in the 6 months before joining. No tacrolimus, mycophenolate mofetil, cyclosporine A, cyclophosphamide or ACTH in the 3 months before joining.
- Main reasons for not taking part
- Nephrotic syndrome caused by another disease, such as purpuric nephritis or lupus nephritis, or a family history of nephrotic syndrome, chronic glomerulonephritis or uremia
- Low blood counts: white blood cells ≤ 3.0 * 10^9 / L, hemoglobin <9.0 g/dL, or platelets <100*10^12/L
- Hepatitis B or hepatitis C infection, or abnormal liver function
- Long-lasting active infections such as Epstein-Barr virus, cytomegalovirus or tuberculosis
- Other autoimmune diseases, inborn immune weakness, tumors, serious heart, liver, kidney, blood or hormone diseases, or another clinical trial in the past 3 months
Show the full registry criteria (16)Hide the full registry criteria
Who can take part
- Sensitive but frequent relapses or steroids dependence nephrotic syndrome
- Age: 2 to 18 years old
- Normal renal function: estimated glomerular filtration rate ≥90ml/ min/1.73m2
- Morning urine protein <1+ or urine protein-creatinine ratio <0.2g/g (<20 mg/ mmol) for 3 consecutive days and above when in enroll
- No rituximab was used within 6 months, no tacrolimus, mycophenolate mofetil, cyclosporine A, or cyclophosphamide was used within 3 months, no ACTH was used within 3 months prior to the enrollment
Who cannot take part
- Those who have participated in other clinical trials within three months prior to the enrollment
- Family history of nephrotic syndrome, chronic glomerulonephritis or uremia
- There are chronic active infections such as Epstein-Barrvirus, cytomegalovirus or Mycobacterium tuberculosis, and the usage of steroids and immunosuppressive agents may aggravate the state of an illness
- Secondary nephrotic syndrome (such as purpuric nephritis, lupus nephritis, etc.)
- Those who with hematological or endocrine system diseases as well as serious organs illness such as heart, liver or kidney
- Those who with other autoimmune diseases or primary immunodeficiencies or tumors
- Leukopenia (White Blood Cells ≤ 3.0 * 10\^9 / L)
- Moderate to severe anemia (hemoglobin <9.0 g/dL)
- Thrombocytopenia (platelet count <100*10\^12/L)
- Positive Hepatitis B virus serological indicators (Hepatitis B surface antigen or / and Hepatitis B virus e antigen or / and Hepatitis B core antibody), Hepatitis C virus-positive or patients with abnormal liver function (2 or more times of alamine aminotransferase or total bilirubin was exceeded the normal value, and continued to rise for 2 weeks)
- Those who was not suitable for participating this study judged by investigator
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Telitacicept
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The main objective is to evaluate the effectiveness of telitacicept in pediatric patients with frequently relapsing or steroid dependent nephrotic syndrome within the 52-week follow-up.
The group in the trial
- Telitacicept groupTreatment being tested
Weekly administration (administration time can be within 1 week + 3 days). Body weight and dosage: for subjects with body weight greater than 10kg and less than or equal to 20kg, the dose of Telitacicept is 40mg; for subjects with body weight greater than 20kg and less than or equal to 40kg, the dose of Telitacicept is 80mg; for subjects with body weight greater than 40kg and less than or equal to 60kg, the dose of Telitacicept is 120mg; for subjects with body weight greater than or equal to 60kg, the dose of Telitacicept is 160mg. Treatment duration: 52 weeks.
Treatment: Telitacicept
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Study of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome
- Plain-language title
- Telitacicept for children with frequently relapsing or steroid-dependent nephrotic syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT06125405, who can take part
- Record updated
- 21 August 2024